Form 4: Director George Poste Receives RSU Grant at Exelixis

Exelixis, Inc. director George Poste was granted 8,367 restricted stock units as part of the company's 2017 Equity Incentive Plan.

Summary

• Director George Poste acquired 8,367 restricted stock units (RSUs) on May 27, 2026.
• The grant was issued under the Exelixis, Inc. 2017 Equity Incentive Plan.
• Each RSU represents the economic equivalent of one share of common stock.
• Following this transaction, the director's total beneficial ownership is 127,199 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial health.

Positives

• Director alignment with shareholder interests through equity-based compensation.
• Standard equity incentive grant consistent with corporate governance practices.

Negatives

• None identified.

Risks

• Vesting of the RSUs is subject to the director's continuous service through May 27, 2027.

Future Outlook

The RSUs are scheduled to vest 100% on May 27, 2027, provided the director maintains continuous service with the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard practice in the biotechnology sector to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The grant structure follows standard industry practices for mid-to-large cap biotech companies.
• Equity compensation for board members is consistent with peer companies like Incyte or BioMarin.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Vesting of the 8,367 RSUs on May 27, 2027.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation